Brief: Neuren Pharmaceuticals Says Daybue Net Sales $66.9 Mln In Q3 2023
03/11/2023 01:18
Nov 3 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX :
* DAYBUE NET SALES US$66.9 MILLION IN Q3 2023
* GUIDANCE PROVIDED FOR NET SALES OF BETWEEN US$80 MILLION
AND
US$87.5 MILLION IN Q4 2024
* SEES NET SALES IN Q4 2023 BETWEEN US$80 MILLION AND
US$87.5
MILLION FOR DAYBUE™ IN UNITED STATES
Source text for Eikon: ID:nASX4cwJbS
Further company coverage: NEU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union